enVVeno Medical Corporation
Last updated September 27, 2026
Organization details
- Legal name
- enVVeno Medical Corporation
- Former names
- Hancock Jaffe Laboratories, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Irvine
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NVNO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001661053
- EIN
- 33-0936180
Board of directors
-
Francis Duhay · DirectorSince 2023
-
Matthew Jenusaitis · DirectorSince 2023
-
Robert Andrew Berman · Director · Chief Executive OfficerSince 2023
-
Robert Gray · DirectorSince 2023
-
Sanjay Shrivastava · DirectorSince 2023
Chief executives
Robert Andrew Berman
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of December 11, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
65.9%
-
89.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,944
- 4 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Francis Duhay Director | Open-market sale | −11 | $11.21 | $123 |
| Jun 11, 2026 | Francis Duhay Director | Open-market sale | −140 | $10.31 | $1,443 |
| Mar 12, 2026 | Francis Duhay Director | Open-market sale | −140 | $11.52 | $1,613 |
| Dec 11, 2025 | Francis Duhay Director | Open-market sale | −4,900 | $0.36 | $1,764 |
| Sep 15, 2025 | Francis Duhay Director | Open-market sale | −4,900 | $0.83 | $4,067 |
| Dec 31, 2024 | Francis Duhay Director | Open-market purchase | +81,433 | $3.07 | $249,999 |
| Dec 31, 2024 | Robert Gray Director | Open-market purchase | +3,500 | $2.94 | $10,290 |
| Dec 24, 2024 | Sanjay Shrivastava Director | Open-market purchase | +5,400 | $2.90 | $15,660 |
| Dec 19, 2024 | Matthew Jenusaitis Director | Open-market purchase | +9,620 | $2.53 | $24,339 |
| Dec 19, 2024 | Robert Andrew Berman Director, Officer (Chief Executive Officer) | Open-market purchase | +12,000 | $2.55 | $30,600 |
| Mar 13, 2024 | Alavi Hamed Officer (Chief Technology Officer) | Option exercise | +8,334 | $3.59 | $29,919 |
| Mar 13, 2024 | Alavi Hamed Officer (Chief Technology Officer) | Open-market sale | −8,334 | $6.22 | $51,837 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.